X4 Pharmaceuticals Key Executives
This section highlights X4 Pharmaceuticals's key executives, including their titles and compensation details.
Find Contacts at X4 Pharmaceuticals
(Showing 0 of )
X4 Pharmaceuticals Earnings
This section highlights X4 Pharmaceuticals's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q4 | 2024 | 2025-03-25 | $-0.17 | $-0.20 |
| Read Transcript | Q3 | 2024 | 2024-11-13 | $-0.17 | $-0.18 |
| Read Transcript | Q1 | 2024 | 2024-05-07 | $-0.17 | $-0.26 |
| Read Transcript | Q4 | 2023 | 2024-03-21 | $-0.15 | $-0.10 |
| Read Transcript | Q3 | 2023 | 2023-11-09 | $-0.15 | $-0.01 |
| Read Transcript | Q2 | 2023 | 2023-08-10 | $-0.17 | $-0.33 |
| Read Transcript | Q1 | 2023 | 2023-05-06 | N/A | N/A |
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was founded in 2010 and is headquartered in Boston, Massachusetts.
$0.20
Stock Price
$34.85M
Market Cap
143
Employees
Boston, MA
Location
Financial Statements
Access annual & quarterly financial statements for X4 Pharmaceuticals, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $2.56M | $- | $- | $- | $3.00M |
| Cost of Revenue | $797.00K | $2.00M | $1.99M | $1.89M | $- |
| Gross Profit | $1.76M | $-2.00M | $-1.99M | $-1.89M | $3.00M |
| Gross Profit Ratio | 68.83% | - | - | - | 100.00% |
| Research and Development Expenses | $81.64M | $70.02M | $61.06M | $50.65M | $41.93M |
| General and Administrative Expenses | $- | $- | $- | $24.70M | $20.94M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $61.52M | $35.51M | $27.02M | $24.70M | $20.94M |
| Other Expenses | $-105.00M | $- | $-6.27M | $-3.57M | $-2.11M |
| Operating Expenses | $38.16M | $107.52M | $88.08M | $75.35M | $62.87M |
| Cost and Expenses | $38.96M | $107.52M | $88.08M | $75.35M | $62.87M |
| Interest Income | $5.77M | $4.58M | $219.00K | $10.00K | $273.00K |
| Interest Expense | $8.77M | $5.78M | $3.99M | $3.64M | $2.69M |
| Depreciation and Amortization | $796.00K | $419.00K | $1.99M | $1.89M | $1.23M |
| EBITDA | $-27.58M | $-107.10M | $-87.57M | $-85.11M | $-58.06M |
| EBITDA Ratio | -1078.45% | - | - | - | -1935.50% |
| Operating Income | $-36.40M | $-107.52M | $-87.57M | $-85.11M | $-59.87M |
| Operating Income Ratio | -1423.58% | - | - | - | -1995.80% |
| Total Other Income Expenses Net | $-739.00K | $6.43M | $-6.27M | $-3.57M | $-2.11M |
| Income Before Tax | $-37.14M | $-101.09M | $-93.84M | $-88.68M | $-61.98M |
| Income Before Tax Ratio | -1452.48% | - | - | - | -2066.10% |
| Income Tax Expense | $310.00K | $78.00K | $28.00K | $17.00K | $148.00K |
| Net Income | $-37.45M | $-101.17M | $-93.87M | $-88.70M | $-62.13M |
| Net Income Ratio | -1464.61% | - | - | - | -2071.03% |
| EPS | $-0.19 | $-0.57 | $-1.48 | $-3.44 | $-3.09 |
| EPS Diluted | $-0.19 | $-0.57 | $-1.48 | $-3.44 | $-3.09 |
| Weighted Average Shares Outstanding | 201.06M | 177.81M | 63.53M | 25.75M | 20.08M |
| Weighted Average Shares Outstanding Diluted | 201.06M | 177.81M | 63.53M | 25.75M | 20.08M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.43M | $560.00K | $563.00K | $- | $3.06M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $0 | $- | $- | $3.00M |
| Cost of Revenue | $302.00K | $227.00K | $268.00K | $62.00K | $62.00K | $502.00K | $516.00K | $512.00K | $501.00K | $494.00K | $500.00K | $499.00K | $494.00K | $491.00K | $487.00K | $420.00K | $- | $- | $- | $- |
| Gross Profit | $1.13M | $333.00K | $295.00K | $-62.00K | $3.00M | $-502.00K | $-516.00K | $-512.00K | $-501.00K | $-494.00K | $-500.00K | $-499.00K | $-494.00K | $-491.00K | $-487.00K | $-420.00K | $0 | $- | $- | $3.00M |
| Gross Profit Ratio | 78.94% | 59.46% | 52.40% | - | 97.97% | - | - | - | - | - | - | - | - | - | - | - | 100.00% | 0.00% | 0.00% | 100.00% |
| Research and Development Expenses | $21.70M | $19.17M | $20.91M | $19.79M | $15.21M | $19.08M | $15.60M | $15.60M | $22.06M | $19.01M | $13.82M | $14.11M | $12.16M | $13.19M | $13.19M | $12.10M | $12.30M | $11.38M | $9.34M | $8.91M |
| General and Administrative Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $14.41M | $14.41M | $6.75M | $7.66M | $7.13M | $5.93M | $5.80M | $5.83M | $5.36M | $5.60M | $5.32M | $4.67M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $-7.17M | $-7.85M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $15.14M | $15.66M | $13.28M | $17.43M | $9.93M | $8.13M | $10.20M | $10.20M | $7.24M | $6.56M | $6.75M | $7.66M | $7.13M | $5.93M | $5.80M | $5.83M | $5.36M | $5.60M | $5.32M | $4.67M |
| Other Expenses | $- | $- | $- | $105.00K | $212.00K | $17.00K | $-29.89M | $-29.89M | $5.29M | $-3.51M | $-59.00K | $60.00K | $-1.15M | $-74.00K | $-635.00K | $186.00K | $-745.00K | $228.00K | $-486.00K | $41.00K |
| Operating Expenses | $36.85M | $34.83M | $34.00M | $37.23M | $25.14M | $27.21M | $25.80M | $25.80M | $29.30M | $25.58M | $20.57M | $21.78M | $19.30M | $19.12M | $19.00M | $17.94M | $17.66M | $16.98M | $14.66M | $13.58M |
| Cost and Expenses | $37.15M | $35.06M | $34.46M | $37.29M | $25.20M | $27.21M | $25.80M | $25.80M | $29.30M | $25.58M | $20.57M | $21.78M | $19.30M | $19.12M | $19.00M | $17.94M | $17.66M | $16.98M | $14.66M | $13.58M |
| Interest Income | $1.27M | $1.87M | $1.56M | $1.07M | $1.45M | $1.39M | $914.00K | $914.00K | $835.00K | $198.00K | $4.00K | $3.00K | $3.00K | $2.00K | $3.00K | $2.00K | $1.00K | $464.00K | $7.00K | $296.00K |
| Interest Expense | $2.30M | $2.41M | $2.18M | $1.87M | $1.89M | $1.63M | $1.15M | $1.15M | $1.11M | $1.14M | $918.00K | $913.00K | $925.00K | $920.00K | $905.00K | $891.00K | $720.00K | $697.00K | $687.00K | $584.00K |
| Depreciation and Amortization | $273.00K | $267.00K | $194.00K | $62.00K | $62.00K | $502.00K | $516.00K | $512.00K | $501.00K | $494.00K | $500.00K | $499.00K | $494.00K | $491.00K | $487.00K | $420.00K | $103.00K | $146.00K | $66.00K | $36.00K |
| EBITDA | $-36.99M | $-34.00M | $-33.70M | $-49.81M | $-17.15M | $-143.00K | $-54.03M | $-22.39M | $-27.45M | $-20.15M | $-19.79M | $-20.53M | $-28.79M | $-19.06M | $-18.24M | $-17.36M | $-17.55M | $-16.83M | $-14.39M | $-10.37M |
| EBITDA Ratio | -2579.22% | -6071.43% | -5986.32% | - | -560.42% | - | - | - | - | - | - | - | - | - | - | - | -585066666666666.75% | - | - | -345.67% |
| Operating Income | $-35.72M | $-34.50M | $71.10M | $-37.29M | $-25.20M | $-27.21M | $-25.80M | $-25.80M | $-22.91M | $-25.58M | $-20.57M | $-21.27M | $-29.05M | $-19.12M | $-19.00M | $-17.94M | $-17.66M | $-16.98M | $-14.66M | $-10.58M |
| Operating Income Ratio | -2490.59% | -6160.71% | 12629.31% | - | -823.50% | - | - | - | - | - | - | - | - | - | - | - | -588500000000000.00% | - | - | -352.70% |
| Total Other Income Expenses Net | $-3.85M | $-2.18M | $19.75M | $-14.46M | $6.10M | $24.93M | $-29.89M | $5.29M | $-3.51M | $-1.45M | $-638.00K | $-674.00K | $-1.15M | $-1.05M | $-635.00K | $-734.00K | $-745.00K | $-469.00K | $-486.00K | $-409.00K |
| Income Before Tax | $-39.56M | $-36.68M | $90.85M | $-51.75M | $-19.10M | $-2.28M | $-55.70M | $-55.70M | $-24.02M | $-29.09M | $-21.21M | $-21.94M | $-30.20M | $-20.17M | $-19.63M | $-18.67M | $-18.40M | $-17.45M | $-15.14M | $-10.99M |
| Income Before Tax Ratio | -2758.93% | -6550.18% | 16136.94% | - | -624.08% | - | - | - | - | - | - | - | - | - | - | - | -613333333333333.25% | - | - | -366.33% |
| Income Tax Expense | $258.00K | $15.00K | $18.00K | $19.00K | $33.00K | $26.00K | $15.00K | $15.00K | $4.00K | $14.00K | $4.00K | $23.00K | $3.00K | $2.00K | $6.00K | $6.00K | $0 | $925.00K | $-66.00K | $148.00K |
| Net Income | $-39.82M | $-36.70M | $90.83M | $-51.77M | $-19.13M | $-2.31M | $-55.71M | $-55.71M | $-24.02M | $-29.10M | $-21.21M | $-21.96M | $-30.21M | $-20.18M | $-19.64M | $-18.68M | $-18.40M | $-17.45M | $-15.14M | $-11.14M |
| Net Income Ratio | -2776.92% | -6552.86% | 16133.75% | - | -625.16% | - | - | - | - | - | - | - | - | - | - | - | -613333333333333.25% | - | - | -371.27% |
| EPS | $-0.20 | $-0.18 | $0.45 | $-0.26 | $-0.10 | $-0.01 | $-0.33 | $-0.38 | $-0.24 | $-0.29 | $-0.60 | $-0.65 | $-1.04 | $-0.76 | $-0.74 | $-0.90 | $-0.91 | $-0.87 | $-0.76 | $-0.56 |
| EPS Diluted | $-0.20 | $-0.18 | $0.45 | $-0.26 | $-0.10 | $-0.01 | $-0.33 | $-0.38 | $-0.24 | $-0.29 | $-0.60 | $-0.65 | $-1.04 | $-0.76 | $-0.74 | $-0.90 | $-0.91 | $-0.87 | $-0.76 | $-0.56 |
| Weighted Average Shares Outstanding | 201.06M | 200.87M | 200.44M | 199.99M | 198.77M | 196.99M | 168.74M | 145.97M | 100.77M | 100.77M | 35.44M | 33.74M | 29.00M | 26.61M | 26.53M | 20.75M | 20.17M | 20.09M | 20.03M | 20.01M |
| Weighted Average Shares Outstanding Diluted | 201.06M | 200.87M | 200.80M | 199.99M | 198.77M | 196.99M | 168.74M | 145.97M | 100.77M | 100.77M | 35.44M | 33.74M | 29.01M | 26.61M | 26.53M | 20.75M | 20.17M | 20.09M | 20.03M | 20.01M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $55.70M | $99.22M | $121.72M | $81.79M | $78.71M |
| Short Term Investments | $46.36M | $15.00M | $- | $- | $- |
| Cash and Short Term Investments | $102.06M | $114.22M | $121.72M | $81.79M | $78.71M |
| Net Receivables | $1.71M | $562.00K | $1.15M | $747.00K | $917.00K |
| Inventory | $2.82M | $- | $- | $- | $- |
| Other Current Assets | $5.59M | $7.30M | $5.81M | $5.34M | $3.68M |
| Total Current Assets | $112.17M | $122.08M | $128.68M | $87.88M | $83.31M |
| Property Plant Equipment Net | $4.84M | $6.39M | $8.33M | $10.22M | $9.20M |
| Goodwill | $17.35M | $17.35M | $17.35M | $17.35M | $27.11M |
| Intangible Assets | $10.00M | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $27.35M | $17.35M | $17.35M | $17.35M | $27.11M |
| Long Term Investments | $- | $- | $1.02M | $1.32M | $1.73M |
| Tax Assets | $- | $- | $-1.02M | $-1.32M | $-1.73M |
| Other Non-Current Assets | $2.08M | $1.44M | $1.23M | $1.72M | $3.26M |
| Total Non-Current Assets | $34.27M | $25.18M | $26.91M | $29.30M | $39.56M |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $146.45M | $147.26M | $155.59M | $117.18M | $122.87M |
| Account Payables | $8.62M | $8.95M | $7.78M | $4.28M | $3.14M |
| Short Term Debt | $1.25M | $1.10M | $3.71M | $2.94M | $1.57M |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $- | $- |
| Other Current Liabilities | $23.00M | $12.82M | $10.84M | $6.79M | $7.23M |
| Total Current Liabilities | $32.88M | $22.86M | $22.32M | $14.02M | $11.95M |
| Long Term Debt | $2.82M | $57.18M | $35.91M | $37.91M | $37.66M |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $88.60M | $16.11M | $23.30M | $826.00K | $462.00K |
| Total Non-Current Liabilities | $91.42M | $73.30M | $59.21M | $38.74M | $38.12M |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $124.30M | $96.16M | $81.53M | $52.76M | $50.07M |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $171.00K | $167.00K | $122.00K | $28.00K | $16.00K |
| Retained Earnings | $-515.36M | $-477.90M | $-376.74M | $-282.87M | $-194.18M |
| Accumulated Other Comprehensive Income Loss | $-122.00K | $-119.00K | $-119.00K | $-119.00K | $-119.00K |
| Other Total Stockholders Equity | $537.46M | $528.96M | $450.79M | $347.37M | $267.08M |
| Total Stockholders Equity | $22.15M | $51.10M | $74.05M | $64.41M | $72.80M |
| Total Equity | $22.15M | $51.10M | $74.05M | $64.41M | $72.80M |
| Total Liabilities and Stockholders Equity | $146.45M | $147.26M | $155.59M | $117.18M | $122.87M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $146.45M | $147.26M | $155.59M | $117.18M | $122.87M |
| Total Investments | $46.36M | $15.00M | $1.02M | $1.32M | $1.73M |
| Total Debt | $2.66M | $58.28M | $38.42M | $39.78M | $38.45M |
| Net Debt | $-53.04M | $-40.94M | $-83.30M | $-42.00M | $-40.26M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $55.70M | $97.41M | $147.22M | $60.49M | $99.47M | $131.58M | $136.43M | $136.43M | $93.41M | $121.72M | $47.38M | $66.43M | $81.79M | $76.39M | $95.16M | $114.94M | $78.71M | $88.81M | $103.74M | $115.05M |
| Short Term Investments | $46.36M | $37.56M | $21.54M | $20.38M | $15.00M | $10.10M | $4.88M | $4.88M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $102.06M | $134.98M | $168.75M | $80.87M | $114.47M | $141.68M | $141.31M | $141.31M | $93.41M | $121.72M | $47.38M | $66.43M | $81.79M | $76.39M | $95.16M | $114.94M | $78.71M | $88.81M | $103.74M | $115.05M |
| Net Receivables | $1.71M | $-4.48M | $854.00K | $702.00K | $562.00K | $393.00K | $820.00K | $- | $- | $909.00K | $843.00K | $868.00K | $747.00K | $646.00K | $1.05M | $768.00K | $917.00K | $629.00K | $509.00K | $3.42M |
| Inventory | $2.82M | $2.44M | $831.00K | $- | $- | $- | $- | $- | $- | $- | $-843.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Current Assets | $5.59M | $10.03M | $4.98M | $5.76M | $7.30M | $5.80M | $5.52M | $8.72M | $6.96M | $5.86M | $4.36M | $3.59M | $5.34M | $3.66M | $5.16M | $4.25M | $3.68M | $4.47M | $5.63M | $3.48M |
| Total Current Assets | $112.17M | $142.97M | $175.42M | $87.33M | $122.08M | $147.87M | $147.65M | $147.65M | $98.22M | $128.68M | $52.59M | $70.88M | $87.88M | $80.70M | $101.37M | $119.96M | $83.31M | $93.91M | $109.89M | $121.95M |
| Property Plant Equipment Net | $4.84M | $5.29M | $5.68M | $6.01M | $6.39M | $6.83M | $7.32M | $7.32M | $7.83M | $8.33M | $9.29M | $9.75M | $10.22M | $10.70M | $11.18M | $11.58M | $9.20M | $9.56M | $2.06M | $2.28M |
| Goodwill | $17.35M | $17.35M | $17.35M | $17.35M | $17.35M | $17.35M | $17.35M | $17.35M | $17.35M | $17.35M | $17.35M | $17.35M | $17.35M | $27.11M | $27.11M | $27.11M | $27.11M | $27.11M | $27.11M | $27.11M |
| Intangible Assets | $10.00M | $10.19M | $10.38M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $27.35M | $27.54M | $27.73M | $17.35M | $17.35M | $17.35M | $17.35M | $17.35M | $17.35M | $17.35M | $17.35M | $17.35M | $17.35M | $27.11M | $27.11M | $27.11M | $27.11M | $27.11M | $27.11M | $27.11M |
| Long Term Investments | $- | $- | $778.00K | $777.00K | $782.00K | $773.00K | $778.00K | $777.00K | $1.02M | $1.29M | $1.30M | $1.32M | $1.32M | $1.33M | $227.00K | $1.72M | $- | $- | $- | $- |
| Tax Assets | $- | $- | $-778.00K | $- | $- | $-773.00K | $-778.00K | $-777.00K | $-1.02M | $-1.29M | $-1.30M | $-1.32M | $-1.32M | $-1.33M | $-227.00K | $-1.72M | $- | $- | $- | $- |
| Other Non-Current Assets | $2.08M | $2.36M | $1.01M | $715.00K | $654.00K | $1.24M | $1.08M | $1.08M | $1.00M | $1.23M | $1.80M | $1.65M | $1.72M | $2.00M | $2.00M | $2.39M | $3.26M | $2.55M | $3.47M | $2.38M |
| Total Non-Current Assets | $34.27M | $35.19M | $35.20M | $24.85M | $25.18M | $25.42M | $25.75M | $25.75M | $26.18M | $26.91M | $28.43M | $28.74M | $29.30M | $39.82M | $40.29M | $41.08M | $39.56M | $39.21M | $32.65M | $31.77M |
| Other Assets | $- | $- | $- | $- | $-0 | $- | $- | $-0 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $146.45M | $178.16M | $210.61M | $112.18M | $147.26M | $173.29M | $173.40M | $173.40M | $124.41M | $155.59M | $81.02M | $99.62M | $117.18M | $120.52M | $141.66M | $161.03M | $122.87M | $133.13M | $142.53M | $153.72M |
| Account Payables | $8.62M | $8.58M | $7.99M | $8.94M | $8.95M | $8.13M | $5.11M | $5.99M | $7.78M | $3.80M | $3.68M | $3.57M | $4.28M | $2.42M | $2.53M | $3.09M | $3.14M | $3.89M | $1.84M | $1.25M |
| Short Term Debt | $1.25M | $1.22M | $2.34M | $1.13M | $2.20M | $2.23M | $3.06M | $1.73M | $2.51M | $15.79M | $10.88M | $5.63M | $2.94M | $2.77M | $1.97M | $1.75M | $1.57M | $1.51M | $1.88M | $1.83M |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Current Liabilities | $23.00M | $19.46M | $18.57M | $13.47M | $11.72M | $15.07M | $14.08M | $11.76M | $12.03M | $9.13M | $7.45M | $5.77M | $6.79M | $8.03M | $8.62M | $9.83M | $7.23M | $7.78M | $7.06M | $4.87M |
| Total Current Liabilities | $32.88M | $29.26M | $28.90M | $23.54M | $22.86M | $25.43M | $22.25M | $22.25M | $19.48M | $22.32M | $22.00M | $14.97M | $14.02M | $13.23M | $13.12M | $14.67M | $11.95M | $13.18M | $10.78M | $7.95M |
| Long Term Debt | $76.83M | $76.98M | $77.06M | $57.14M | $57.18M | $57.17M | $34.96M | $35.20M | $35.91M | $22.53M | $28.63M | $34.29M | $37.91M | $38.11M | $38.89M | $38.94M | $37.66M | $30.21M | $26.84M | $26.95M |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $14.59M | $12.30M | $10.20M | $30.46M | $16.11M | $23.10M | $48.65M | $18.04M | $23.30M | $312.00K | $314.00K | $650.00K | $826.00K | $496.00K | $434.00K | $491.00K | $462.00K | $25.00K | $26.00K | $26.00K |
| Total Non-Current Liabilities | $91.42M | $89.29M | $87.26M | $87.61M | $73.30M | $80.27M | $83.61M | $83.61M | $53.25M | $59.21M | $28.94M | $34.94M | $38.74M | $38.61M | $126.66M | $39.43M | $38.12M | $30.24M | $26.87M | $26.98M |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $124.30M | $118.54M | $116.16M | $111.15M | $96.16M | $105.70M | $105.86M | $105.86M | $72.73M | $81.53M | $50.95M | $49.91M | $52.76M | $51.84M | $139.78M | $54.10M | $50.07M | $43.42M | $37.65M | $34.93M |
| Preferred Stock | $- | $- | $- | $- | $- | $458.73M | $- | $- | $- | $- | $- | $- | $- | $- | $1.88M | $1.88M | $194.18M | $- | $- | $- |
| Common Stock | $171.00K | $168.00K | $168.00K | $168.00K | $167.00K | $165.00K | $164.00K | $164.00K | $122.00K | $122.00K | $31.00K | $31.00K | $28.00K | $25.00K | $1.88M | $1.90M | $16.00K | $16.00K | $16.00K | $16.00K |
| Retained Earnings | $-515.36M | $-475.53M | $-438.84M | $-529.67M | $-477.90M | $-458.77M | $-456.47M | $-456.47M | $-400.76M | $-376.74M | $-326.05M | $-304.84M | $-282.87M | $-252.66M | $-232.49M | $-212.85M | $-194.18M | $-175.78M | $-158.33M | $-143.18M |
| Accumulated Other Comprehensive Income Loss | $-122.00K | $-114.00K | $-159.00K | $-155.00K | $-119.00K | $-119.00K | $-119.00K | $-119.00K | $-119.00K | $-119.00K | $-119.00K | $-119.00K | $-119.00K | $-119.00K | $-119.00K | $-119.00K | $-119.00K | $-119.00K | $-119.00K | $-119.00K |
| Other Total Stockholders Equity | $537.46M | $535.10M | $533.28M | $530.69M | $528.96M | $526.32M | $523.96M | $452.43M | $450.79M | $409.53M | $356.21M | $354.64M | $347.37M | $321.44M | $319.92M | $318.01M | $267.08M | $265.59M | $263.31M | $262.08M |
| Total Stockholders Equity | $22.15M | $59.62M | $94.45M | $1.04M | $51.10M | $67.59M | $67.53M | $67.53M | $51.68M | $74.05M | $30.07M | $49.71M | $64.41M | $68.68M | $1.88M | $106.94M | $72.80M | $89.71M | $104.88M | $118.79M |
| Total Equity | $22.15M | $59.62M | $94.45M | $1.04M | $51.10M | $67.59M | $67.53M | $67.53M | $51.68M | $74.05M | $30.07M | $49.71M | $64.41M | $68.68M | $1.88M | $106.94M | $72.80M | $89.71M | $104.88M | $118.79M |
| Total Liabilities and Stockholders Equity | $146.45M | $178.16M | $210.61M | $112.18M | $147.26M | $173.29M | $173.40M | $173.40M | $124.41M | $155.59M | $81.02M | $99.62M | $117.18M | $120.52M | $141.66M | $161.03M | $122.87M | $133.13M | $142.53M | $153.72M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $146.45M | $178.16M | $210.61M | $112.18M | $147.26M | $173.29M | $173.40M | $173.40M | $124.41M | $155.59M | $81.02M | $99.62M | $117.18M | $120.52M | $141.66M | $161.03M | $122.87M | $133.13M | $142.53M | $153.72M |
| Total Investments | $46.36M | $37.56M | $22.31M | $21.15M | $15.78M | $10.10M | $4.88M | $4.88M | $1.02M | $1.29M | $1.30M | $1.32M | $1.32M | $1.33M | $227.00K | $1.72M | $- | $- | $- | $- |
| Total Debt | $78.09M | $78.20M | $78.23M | $58.27M | $58.28M | $58.29M | $36.87M | $36.87M | $36.93M | $38.42M | $38.37M | $38.81M | $39.78M | $39.84M | $39.88M | $39.81M | $38.45M | $30.97M | $27.78M | $27.87M |
| Net Debt | $22.39M | $-19.21M | $-68.99M | $-2.22M | $-41.19M | $-73.30M | $-99.56M | $-99.56M | $-56.47M | $-83.30M | $-9.01M | $-27.61M | $-42.00M | $-36.55M | $-55.28M | $-75.14M | $-40.26M | $-57.84M | $-75.96M | $-87.19M |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $-37.45M | $-101.17M | $-93.87M | $-88.70M | $-62.13M |
| Depreciation and Amortization | $796.00K | $419.00K | $513.00K | $499.00K | $351.00K |
| Deferred Income Tax | $- | $- | $- | $-6.68M | $-5.78M |
| Stock Based Compensation | $8.20M | $8.69M | $5.20M | $6.18M | $5.43M |
| Change in Working Capital | $- | $344.00K | $5.74M | $-1.50M | $-4.06M |
| Accounts Receivables | $-1.07M | $- | $-610.00K | $- | $- |
| Inventory | $-2.82M | $- | $610.00K | $- | $- |
| Accounts Payables | $-286.00K | $1.23M | $3.42M | $1.17M | $1.03M |
| Other Working Capital | $- | $-890.00K | $2.31M | $-2.66M | $-5.09M |
| Other Non Cash Items | $-102.45M | $-4.79M | $5.32M | $19.29M | $7.38M |
| Net Cash Provided by Operating Activities | $-130.90M | $-96.51M | $-77.10M | $-70.91M | $-58.82M |
| Investments in Property Plant and Equipment | $-326.00K | $-60.00K | $-103.00K | $-615.00K | $-1.36M |
| Acquisitions Net | $- | $- | $- | $- | $- |
| Purchases of Investments | $-57.13M | $-16.82M | $-4.80M | $- | $- |
| Sales Maturities of Investments | $26.45M | $2.00M | $- | $- | $- |
| Other Investing Activities | $98.00M | $- | $4.80M | $- | $- |
| Net Cash Used for Investing Activities | $66.99M | $-14.88M | $-103.00K | $-615.00K | $-1.36M |
| Debt Repayment | $20.00M | $20.44M | $-795.00K | $- | $12.39M |
| Common Stock Issued | $- | $60.00M | $122.63M | $75.98M | $-277.00K |
| Common Stock Repurchased | $- | $- | $- | $-2.00M | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $294.00K | $8.08M | $-4.61M | $260.00K | $283.00K |
| Net Cash Used Provided by Financing Activities | $20.29M | $88.52M | $117.23M | $74.25M | $12.39M |
| Effect of Forex Changes on Cash | $-156.00K | $99.00K | $-105.00K | $-319.00K | $402.00K |
| Net Change in Cash | $-43.77M | $-22.78M | $39.92M | $2.41M | $-47.38M |
| Cash at End of Period | $56.48M | $100.25M | $123.03M | $83.11M | $80.70M |
| Cash at Beginning of Period | $100.25M | $123.03M | $83.11M | $80.70M | $128.09M |
| Operating Cash Flow | $-130.90M | $-96.51M | $-77.10M | $-70.91M | $-58.82M |
| Capital Expenditure | $-326.00K | $-60.00K | $-103.00K | $-615.00K | $-1.36M |
| Free Cash Flow | $-131.23M | $-96.57M | $-77.20M | $-71.52M | $-60.18M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-39.82M | $-36.70M | $90.83M | $-51.77M | $-19.13M | $-2.31M | $-55.71M | $-55.71M | $-24.02M | $-29.10M | $-21.21M | $-21.96M | $-30.21M | $-20.18M | $-19.64M | $-18.68M | $-18.40M | $-17.45M | $-15.14M | $-11.14M |
| Depreciation and Amortization | $273.00K | $267.00K | $194.00K | $62.00K | $62.00K | $104.00K | $126.00K | $126.00K | $127.00K | $124.00K | $132.00K | $133.00K | $132.00K | $132.00K | $129.00K | $106.00K | $103.00K | $146.00K | $66.00K | $36.00K |
| Deferred Income Tax | $- | $- | $- | $- | $-1.85M | $-25.16M | $-2.27M | $-2.27M | $- | $- | $- | $- | $10.12M | $- | $-3.29M | $- | $-5.94M | $- | $-2.05M | $162.00K |
| Stock Based Compensation | $2.22M | $1.82M | $2.43M | $1.74M | $2.54M | $2.36M | $2.14M | $1.65M | $1.11M | $1.11M | $1.52M | $1.46M | $1.61M | $1.52M | $1.80M | $1.26M | $1.40M | $2.24M | $1.17M | $613.00K |
| Change in Working Capital | $1.20M | $-3.14M | $1.05M | $2.09M | $-5.36M | $3.54M | $1.55M | $1.55M | $616.00K | $5.47M | $691.00K | $-300.00K | $-1.33M | $3.50M | $-1.95M | $-1.72M | $-1.28M | $514.00K | $2.25M | $-5.55M |
| Accounts Receivables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $3.00M | $- | $3.00K | $-3.00M |
| Inventory | $-372.00K | $-2.44M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Accounts Payables | $78.00K | $580.00K | $-948.00K | $4.00K | $808.00K | $3.24M | $-1.10M | $-1.10M | $-1.71M | $3.91M | $108.00K | $-713.00K | $1.86M | $-103.00K | $-569.00K | $-23.00K | $910.00K | $332.00K | $589.00K | $-800.00K |
| Other Working Capital | $1.49M | $-1.27M | $2.00M | $2.09M | $-6.17M | $299.00K | $2.65M | $2.65M | $1.71M | $1.57M | $583.00K | $413.00K | $-3.19M | $3.60M | $-1.38M | $-1.70M | $-5.19M | $182.00K | $1.66M | $-1.75M |
| Other Non Cash Items | $3.14M | $3.71M | $-124.78M | $16.14M | $-4.00M | $636.00K | $32.74M | $32.74M | $-4.88M | $3.31M | $393.00K | $444.00K | $615.00K | $816.00K | $3.75M | $591.00K | $6.62M | $217.00K | $2.24M | $347.00K |
| Net Cash Provided by Operating Activities | $-32.99M | $-34.03M | $-30.28M | $-33.60M | $-27.75M | $-20.83M | $-21.43M | $-21.43M | $-26.51M | $-19.09M | $-18.47M | $-20.23M | $-19.05M | $-14.21M | $-19.20M | $-18.44M | $-17.50M | $-14.33M | $-11.46M | $-15.53M |
| Investments in Property Plant and Equipment | $-41.00K | $-92.00K | $-134.00K | $-59.00K | $-35.00K | $-8.00K | $-8.00K | $-8.00K | $-9.00K | $-34.00K | $-38.00K | $-22.00K | $-13.00K | $-20.00K | $-86.00K | $-496.00K | $-302.00K | $-496.00K | $-9.00K | $-555.00K |
| Acquisitions Net | $- | $- | $- | $- | $4.80K | $-1.00M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $-22.78M | $-21.09M | $-3.00M | $-10.26M | $-5.80M | $-6.15M | $-4.88M | $- | $-4.80M | $-4.80M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $14.20M | $5.25M | $2.00M | $5.00M | $1.00M | $1.00M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Investing Activities | $- | $- | $98.00M | $-59.00K | $-4.80K | $1.00M | $-4.88K | $-4.88M | $4.80M | $4.80M | $- | $-22.00K | $- | $- | $- | $-496.00K | $- | $- | $- | $-555.00K |
| Net Cash Used for Investing Activities | $-8.62M | $-15.93M | $96.86M | $-5.32M | $-4.83M | $-5.16M | $-4.88M | $-4.88M | $-9.00K | $-34.00K | $-38.00K | $-22.00K | $-13.00K | $-20.00K | $-86.00K | $-496.00K | $-302.00K | $-496.00K | $-9.00K | $-555.00K |
| Debt Repayment | $- | $- | $20.00M | $- | $- | $21.74M | $381.00K | $-1.68M | $- | $439.00K | $-325.00K | $-909.00K | $- | $- | $- | $- | $7.50M | $- | $- | $4.89M |
| Common Stock Issued | $-159.00K | $159.00K | $159.00K | $- | $97.00K | $-283.00K | $68.89M | $- | $62.01M | $54.77M | $-22.00K | $5.88M | $24.47M | $-2.44M | $-924.00K | $55.00M | $- | $- | $- | $- |
| Common Stock Repurchased | $- | $- | $- | $- | $281 | $- | $443.00K | $-443.00K | $- | $- | $- | $- | $- | $-4.44K | $-924 | $- | $36.00K | $-264.00K | $-14 | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $294.00K | $-159.00K | $159.00K | $- | $97.00K | $-248.00K | $8.23M | $- | $-1.36M | $-3.23M | $- | $-12.00K | $103.00K | $- | $116.00K | $41.00K | $93.00K | $29.00K | $65.00K | $96.00K |
| Net Cash Used Provided by Financing Activities | $135.00K | $- | $20.16M | $- | $97.00K | $21.20M | $69.34M | $69.34M | $-2.12M | $60.64M | $-347.00K | $4.96M | $24.57M | $-4.44M | $-924.00K | $55.04M | $7.63M | $-284.00K | $65.00K | $4.98M |
| Effect of Forex Changes on Cash | $-244.00K | $165.00K | $-18.00K | $-59.00K | $127.00K | $-72.00K | $-6.00K | $-6.00K | $50.00K | $363.00K | $-202.00K | $-69.00K | $-116.00K | $-100.00K | $40.00K | $-143.00K | $162.00K | $180.00K | $94.00K | $-34.00K |
| Net Change in Cash | $-41.73M | $-49.02M | $86.72M | $-38.97M | $-32.36M | $-4.85M | $43.02M | $43.02M | $-28.59M | $41.88M | $-19.06M | $-15.36M | $5.39M | $-18.77M | $-20.17M | $35.96M | $-10.02M | $-14.93M | $-11.31M | $-11.13M |
| Cash at End of Period | $56.48M | $98.20M | $147.22M | $60.49M | $99.47M | $132.60M | $137.46M | $137.46M | $94.43M | $123.03M | $48.68M | $67.74M | $83.11M | $77.72M | $96.49M | $116.66M | $80.70M | $90.72M | $105.64M | $116.95M |
| Cash at Beginning of Period | $98.20M | $147.22M | $60.49M | $99.47M | $131.83M | $137.46M | $94.43M | $94.43M | $123.03M | $81.15M | $67.74M | $83.11M | $77.72M | $96.49M | $116.66M | $80.70M | $90.72M | $105.64M | $116.95M | $128.09M |
| Operating Cash Flow | $-32.99M | $-34.03M | $-30.28M | $-33.60M | $-27.75M | $-20.83M | $-21.43M | $-21.43M | $-26.51M | $-19.09M | $-18.47M | $-20.23M | $-19.05M | $-14.21M | $-19.20M | $-18.44M | $-17.50M | $-14.33M | $-11.46M | $-15.53M |
| Capital Expenditure | $-41.00K | $-92.00K | $-134.00K | $-59.00K | $-35.00K | $-8.00K | $-8.00K | $-8.00K | $-9.00K | $-34.00K | $-38.00K | $-22.00K | $-13.00K | $-20.00K | $-86.00K | $-496.00K | $-302.00K | $-496.00K | $-9.00K | $-555.00K |
| Free Cash Flow | $-33.04M | $-34.12M | $-30.41M | $-33.66M | $-27.78M | $-20.84M | $-21.43M | $-21.43M | $-26.52M | $-19.13M | $-18.51M | $-20.25M | $-19.07M | $-14.23M | $-19.28M | $-18.94M | $-17.81M | $-14.82M | $-11.47M | $-16.08M |
X4 Pharmaceuticals Dividends
Explore X4 Pharmaceuticals's dividend history, including dividend yield, payout ratio, and historical payments.
X4 Pharmaceuticals News
Read the latest news about X4 Pharmaceuticals, including recent articles, headlines, and updates.
X4 Pharmaceuticals, Inc. (XFOR) Q4 2024 Earnings Call Transcript
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR ) Q4 2024 Earnings Conference Call March 25, 2025 8:30 AM ET Company Participants Daniel Ferry - IR, LifeSci Advisors Paula Ragan - CEO Adam Mostafa - CFO Christophe Arbet-Engels - Chief Medical Officer Mark Baldry - CCO Conference Call Participants Stephen Willey - Stifel Ed Tenthoff - Piper Sandler Ayan Hussein - Cantor Fitzgerald Doug MacPherson - H.C. Wainwright David Bautz - Zacks Small-Cap Research Operator Greetings, and welcome to the X4 Pharmaceuticals Fourth Quarter and Full Year 2024 Financial and Operating Results Conference Call.
X4 Pharmaceuticals to Report Fourth-Quarter and Full-Year 2024 Financial Results and Host a Conference Call and Webcast on March 25, 2025
BOSTON, March 11, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2024 and provide corporate updates on Tuesday, March 25, 2025.
X4 Pharmaceuticals and taiba rare Announce Exclusive Agreement for the Distribution and Commercialization of XOLREMDI® (mavorixafor) in WHIM Syndrome in Select Middle East Countries
Agreement covers Saudi Arabia, United Arab Emirates, Qatar, Oman, Kuwait, Bahrain, and Egypt Agreement covers Saudi Arabia, United Arab Emirates, Qatar, Oman, Kuwait, Bahrain, and Egypt
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on January 31, 2025, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement awards consist of options to purchase an aggregate of 130,117 shares of X4's common stock. These stock awards were granted as an inducement material to the new employees entering into employment with X4 in accordance with Nasdaq Listing Rule 5635(c)(4) and were approved by X4's Compensation Committee of the Board of Directors.
X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor for the Treatment of WHIM Syndrome
Submission supported by positive results from global, Phase 3 4WHIM clinical trial; U.S. regulatory approval in WHIM syndrome granted in 2024 Decision on MAA expected in 1H 2026 BOSTON, Jan. 24, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that its Marketing Authorization Application (MAA) for mavorixafor for the treatment of WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis), a rare primary immunodeficiency, has been validated for review and is now under evaluation with the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP). The EMA previously granted orphan designation to mavorixafor in WHIM syndrome.
X4 Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize Mavorixafor in Europe, Australia, and New Zealand
X4 to receive a €28.5 million upfront payment and up to €226 million in potential regulatory and commercial milestone payments in addition to tiered, double-digit royalties up to the mid-twenties
X4 Pharmaceuticals to Participate in the Stifel 2024 Healthcare Conference
BOSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that management will participate in the Stifel 2024 Healthcare Conference, taking place in New York, NY on November 18-19, 2024.
X4 Pharmaceuticals, Inc. (XFOR) Q3 2024 Earnings Call Transcript
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR ) Q3 2024 Earnings Conference Call November 13, 2024 8:00 AM ET Company Participants Daniel Ferry - IR, LifeSci Advisors Paula Ragan - CEO Christophe Arbet-Engels - Chief Medical Officer Mark Baldry - CCO Conference Call Participants Kristen Kluska - Cantor Edward Tenthoff - Piper Sandler Swayampakula Ramakanth - H.C. Wainwright Stephen Willey - Stifel David Bautz - Zacks Operator Greetings, and welcome to the X4 Pharmaceuticals Call and Webcast.
X4 Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Positive results from completed Phase 2 study of mavorixafor in chronic neutropenia (CN) announced today Pivotal Phase 3 trial of mavorixafor in CN on track to fully enroll in mid-2025 U.S. launch of XOLREMDI® (mavorixafor) in WHIM underway; submission of Marketing Authorization Application (MAA) to European Medicines Agency (EMA) expected by early 2025 Conference call and webcast today at 8:00 a.m. ET BOSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today reported financial results for the third quarter ended September 30, 2024 and highlighted recent and key upcoming expected milestones.
X4 Pharmaceuticals Announces Positive Results from Completed Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN)
Mavorixafor durably and meaningfully elevated participants' mean absolute neutrophil counts (ANC) Mavorixafor enabled substantial reductions in G-CSF dosing while maintaining mean ANC at normal levels Phase 2 study results and new analysis confirming functionality of neutrophils in sub-study participants bolster confidence in achieving success in Phase 3 4WARD trial Company conference call and webcast today at 8:00 am ET BOSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced positive new clinical data from its now completed Phase 2 clinical trial evaluating mavorixafor, an oral CXCR4 antagonist, in the treatment of people with chronic neutropenia (CN). An analysis of final data from the six-month study showed that once-daily oral mavorixafor durably and meaningfully increased participants' mean absolute neutrophil counts (ANC).
X4 Pharmaceuticals to Report Third-Quarter 2024 Financial and Phase 2 Chronic Neutropenia Study Results During Conference Call and Webcast on November 13, 2024
BOSTON, Oct. 24, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will report financial results for the third quarter ended September 30, 2024 and present results from its concluded Phase 2 clinical trial evaluating mavorixafor in people with chronic neutropenia on Wednesday, November 13, 2024.
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Oct. 01, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on September 30, 2024, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement awards consist of options to purchase an aggregate of 744,468 shares of X4's common stock. These stock awards were granted as an inducement material to the new employees entering into employment with X4 in accordance with Nasdaq Listing Rule 5635(c)(4) and were approved by X4's Compensation Committee of the Board of Directors.
X4 Pharmaceuticals to Participate in Upcoming September Investor Conferences
BOSTON, Aug. 28, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that management will be participating in three upcoming investor conferences in September 2024:
X4 Pharmaceuticals, Inc. (XFOR) Q2 2024 Earnings Call Transcript
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR ) Q2 2024 Results Conference Call August 8, 2024 8:30 AM ET Company Participants Dan Ferry - IR Paula Ragan - CEO Adam Mostafa - CFO Mark Baldry - CCO Conference Call Participants David Bautz - Zacks Small-Cap Research Stephen Willey - Stifel Leah Cann - Brookline Capital Markets RK - H.C. Wainwright Ed Tenthoff - Piper Sandler Kristen Kluska - Cantor Operator Good morning, everyone, and welcome to X4 Pharmaceuticals Second Quarter 2024 Earnings Conference Call.
X4 Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
First U.S. commercial sales of XOLREMDI™ (mavorixafor) following April 2024 FDA approval Positive interim data from Phase 2 trial of mavorixafor in chronic neutropenia; full trial results expected in November 2024 Initiated global, pivotal Phase 3 trial of mavorixafor in chronic neutropenia Conference call to be hosted today at 8:30 a.m. ET BOSTON, Aug. 08, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today reported financial results for the second quarter ended June 30, 2024 and highlighted key recent and upcoming expected milestones.
X4 Pharmaceuticals: Catch The Falling Knife After Propitious Mavorixafor Data
X4 Pharmaceuticals, Inc. stock price dropped due to the discontinuation of Phase II study for chronic neutropenia, but the potential market for mavorixafor is substantial. X4 Pharmaceuticals is targeting rare diseases with mavorixafor, approved for WHIM syndrome, and moving forward with a Phase III trial for CN. X4 Pharmaceuticals has the potential for significant growth with mavorixafor addressing multiple rare diseases, but faces risks including FDA approval and market penetration.
X4 Pharmaceuticals Announces Positive Interim Clinical Data from Ongoing Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN) and Initiation of Pivotal Phase 3 CN Trial
100% of evaluable participants at Month 6 achieved target absolute neutrophil count (ANC) increase with once-daily, oral mavorixafor +/- stable-dose G-CSF as of the interim analysis data cut-off date
X4 Pharmaceuticals to Host Virtual Investor Event on June 27, 2024 to Review New Mavorixafor Clinical Data from Ongoing Phase 2 Trial in Chronic Neutropenia
Webcast to include interim hematological results from at least 15 trial participants and feature experts in the treatment of chronic neutropenia Webcast to include interim hematological results from at least 15 trial participants and feature experts in the treatment of chronic neutropenia
X4 Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
BOSTON, May 13, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that management will be participating in the upcoming H.C. Wainwright 2nd Annual BioConnect Investor Conference, taking place on May 20th, 2024, at the Nasdaq Stock Exchange in New York City.
X4 Pharmaceuticals Announces $125 Million Capital Infusion from $105 Million Sale of Priority Review Voucher and $20 Million Drawdown from Existing Loan Facility
$125 million of non-dilutive capital extends projected cash runway into late 2025, excluding expected commercial sales from XOLREMDI™ (mavorixafor)
X4 Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates
U.S. launch underway for XOLREMDI™ (mavorixafor) in WHIM syndrome XOLREMDI Phase 3 4WHIM clinical trial data published online in Blood, the journal of the American Society of Hematology Presentation of interim clinical data from the ongoing mavorixafor Phase 2 trial in chronic neutropenia expected at a planned company investor event in June 2024 Conference call to be hosted today at 8:30 a.m. ET BOSTON, May 07, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today reported financial results for the first quarter ended March 31, 2024 and highlighted key recent and upcoming expected milestones.
X4 Pharmaceuticals to Report First-Quarter 2024 Financial Results and Host a Conference Call and Webcast on May 7, 2024
BOSTON, April 30, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will be reporting financial results for the first quarter ended March 31, 2024 and providing corporate updates on Tuesday, May 7, 2024.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for XFOR.